2001
DOI: 10.1034/j.1399-6576.2001.045005583.x
|View full text |Cite
|
Sign up to set email alerts
|

Inclusion of lignocaine base into a polar lipid formulation –in vitro release, duration of peripheral nerve block and arterial blood concentrations in the rat

Abstract: Our findings indicate that lignocaine base in polar lipids acts as a slow-release preparation of local anaesthetic both in vitro and in vivo.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

1
6
0
2

Year Published

2005
2005
2010
2010

Publication Types

Select...
3
1
1

Relationship

0
5

Authors

Journals

citations
Cited by 27 publications
(9 citation statements)
references
References 12 publications
(14 reference statements)
1
6
0
2
Order By: Relevance
“…However, because depot formulations of local anesthetics are mainly designed to produce reversible nerve blocks for postoperative pain, the findings were troubling and raised the question of whether long duration of action with such formulations must be bought at the price of more or less severe neurotoxicity. This question prompted a second study on formulations that mainly contain bupivacaine as the active substance, in concentrations higher than in licensed preparations, as well as a test of the possible neurotoxicity of some earlier reported formu-lations 21,22 with otherwise promising pharmaceutical and pharmacologic characteristics.…”
Section: Discussionmentioning
confidence: 99%
See 4 more Smart Citations
“…However, because depot formulations of local anesthetics are mainly designed to produce reversible nerve blocks for postoperative pain, the findings were troubling and raised the question of whether long duration of action with such formulations must be bought at the price of more or less severe neurotoxicity. This question prompted a second study on formulations that mainly contain bupivacaine as the active substance, in concentrations higher than in licensed preparations, as well as a test of the possible neurotoxicity of some earlier reported formu-lations 21,22 with otherwise promising pharmaceutical and pharmacologic characteristics.…”
Section: Discussionmentioning
confidence: 99%
“…Furthermore, four previously described formulations were studied: 4.2% and 7.0% of bupivacaine base in MCT, 22 20% lidocaine base in SPC/GD, and pure SPC/GD vehicle. 21 The MCT formulations were prepared by mixing the components in a glass vial and melting to a homogenous transparent liquid, at a maximum temperature of 90°C. They were then cooled in a water bath to 10°C.…”
Section: Formulation Of Drugsmentioning
confidence: 99%
See 3 more Smart Citations